Progressive Supranuclear Palsy (PSP) is a brain disease that slowly worsens over time. “Progressive” means it gradually gets worse. “Supranuclear” means the problem sits above the eye-movement control centers in the brainstem, so the signals that tell the eyes to move are interrupted before they reach the eye-movement nerves. “Palsy” means weakness or loss of control. In simple terms, PSP is a condition where certain brain cells, especially in the midbrain and nearby areas, become sick and die. These cells control balance, eye movements, body posture, speech, swallowing, and thinking skills like planning and attention. Because these cells get damaged, people with PSP often have early balance problems, trouble looking up and down, stiff posture, slow movements, and changes in speech and swallowing. Thinking can also slow down, especially for tasks that need planning or quick decisions.
Progressive supranuclear palsy (PSP) is a degenerative brain disease that mainly affects the brainstem and nearby networks that control eye movement, balance, walking, speech, swallowing, and thinking. “Progressive” means symptoms steadily get worse over time. “Supranuclear” means the problem sits above the eye-movement nerves in the brainstem, so the eyes can move normally but the brain’s control signals don’t get through well. “Palsy” means weakness or movement difficulty. PSP belongs to the “tauopathies,” conditions where the protein tau builds up abnormally inside brain cells; in PSP the build-up is a 4-repeat tau pattern. Typical red flags are early backward falls, trouble looking up or down (especially down), stiff and slow trunk-dominant movement, slurred speech, swallowing difficulty, and changes in planning, attention, mood, or behavior. There is no cure yet, but many therapies can reduce symptoms, improve safety, and support quality of life. NINDSPMCBMJ Pain News
A key biological feature of PSP is the build-up of a normal brain protein called tau in an abnormal form. Tau helps keep the inner “tracks” of nerve cells stable. In PSP, the tau protein becomes excessively modified and clumps inside brain cells. These clumps disturb cell function and lead to cell death. PSP is not the same as Parkinson’s disease, though some symptoms can overlap. PSP usually responds poorly to typical Parkinson’s drugs, and eye-movement problems and early falls are more prominent in PSP. PSP is not caused by anything a person did. It is usually not inherited in a simple way and most cases happen without a clear family pattern. There is no single blood test that proves PSP. Doctors diagnose it by listening to the history, examining eye movements and balance, and using brain scans and other tests to rule out look-alike conditions.
Types of PSP
Doctors use “phenotypes” or clinical patterns to describe how PSP shows up in real life. The underlying biology is similar, but the first and main symptoms can differ from person to person. Naming the pattern helps predict which problems are likely to appear and guides care and safety planning.
PSP–Richardson syndrome (PSP-RS).
This is the classic and most common form. People develop early trouble with balance and often fall backward within the first year or two. Eye movements, especially looking down and up, slowly become limited. The posture becomes stiff and upright, and the neck can pull back. Speech becomes soft or slurred, and swallowing gets harder. Thinking slows, especially planning, multitasking, and attention.PSP–Parkinsonism (PSP-P).
This pattern can look more like Parkinson’s disease at first, with tremor being mild or absent, but slowness and stiffness are present. There may be a partial, short-lived response to levodopa. Eye-movement problems and early falls appear later than in PSP-RS.PSP with pure akinesia and gait freezing (PSP-PAGF).
The leading issue is “freezing” of walking, where the feet feel glued to the floor, especially when starting to walk or turning. Tremor is usually absent, and eye-movement problems show up later. Speech can become low and rushed.PSP with corticobasal syndrome (PSP-CBS).
Movement problems mainly affect one side of the body, with stiffness, awkward postures, and trouble using the arm or hand for complex tasks. There can be “alien limb” feelings. Eye-movement and balance issues of PSP still develop over time.PSP with frontal (behavioral) presentation (PSP-F).
Changes in personality and behavior come early. People may become apathetic, impulsive, or socially disinhibited. Planning, decision-making, and attention are clearly affected. The eye and balance problems of PSP appear as the disease progresses.PSP with speech/language presentation (PSP-SL).
Speech becomes effortful and non-fluent. Words come out slowly with broken rhythm and grammar. Comprehension of complex sentences can be difficult. Over time, postural and eye-movement problems reveal the PSP pattern.PSP with ocular motor predominance (PSP-OM).
The earliest sign is a problem with fast eye movements (saccades), especially up-and-down. People feel they cannot look down well to read or manage stairs. Balance problems and falls follow.PSP with postural-instability predominance (PSP-PI).
Early and frequent falls and severe instability dominate. Eye-movement and speech issues appear, but later.
These patterns can overlap and can change as the condition advances. The exact label is less important than recognizing the shared needs: fall prevention, eye-movement and vision support, speech and swallow care, and help with planning tasks.
Causes and contributors
PSP does not have a single simple cause like an infection you catch. It is best understood as a biological process where several factors push the brain’s tau system off balance. Below are 20 evidence-informed drivers and contributors. To keep this simple and honest, think of them as biological reasons and risk influences, not all as proven direct “causes” in every person:
Abnormal tau protein build-up (core driver).
In PSP, a specific form of tau (often called 4-repeat tau) builds up inside nerve cells and supporting glial cells. These tau clumps disrupt cell transport and signaling and lead to cell death.Excessive tau phosphorylation.
Chemical changes are added to tau at many sites. Over-phosphorylated tau lets go of the cell’s internal tracks (microtubules), becomes sticky, and forms toxic aggregates.MAPT gene haplotype risk (H1 haplotype).
The gene that makes tau (MAPT) has common versions. The H1 version is more frequent in PSP. It does not “cause” PSP by itself, but it increases susceptibility.Other genetic risk loci (e.g., STX6).
Large genetic studies have found additional risk signals in genes involved in cellular transport and protein handling. These are small effects that tilt risk rather than guarantee disease.Myelin and oligodendrocyte involvement (MOBP region).
Genetic signals near myelin-related genes suggest that white-matter support cells also get involved, which may help explain gait and postural problems.Endoplasmic reticulum stress and protein quality control (e.g., EIF2AK3/PERK).
Cells under stress activate “unfolded protein” responses. If these systems are overwhelmed, abnormal proteins build up, damaging cells.Microtubule instability.
Tau normally stabilizes microtubules, the inner rails of nerve cells. When tau is abnormal, these rails break down and axonal transport fails, starving nerve endings of needed supplies.Mitochondrial dysfunction and energy failure.
Sick neurons make energy less efficiently. Energy shortfalls make them more vulnerable to stress and toxins, especially in the midbrain.Neuroinflammation (microglia activation).
Brain immune cells become activated. Some inflammation may start as a response to injury but can become harmful if it stays high.Astrocyte dysfunction (tufted astrocytes).
Supporting cells that maintain the chemical environment around neurons also accumulate tau. When they fail, neurons lose protection.Impaired protein clearance (autophagy-lysosome pathways).
Cells normally clear damaged proteins. When these pathways slow or clog, tau accumulates faster.Prion-like spread of tau pathology along brain networks.
Abnormal tau can seed more abnormal tau in connected regions, spreading dysfunction from one node to another.Aging (strongest non-genetic factor).
Cell repair systems weaken with age. Most PSP begins in the 60s–70s, showing that aging biology is a key background driver.Male sex (epidemiologic association).
PSP is reported somewhat more often in men. This may reflect biological or exposure differences.Environmental toxin exposure (possible contributor).
Some studies suggest links between certain pesticides or solvents and tau disorders, but evidence is mixed and not definitive.Head trauma history (uncertain contribution).
Head injury can disturb tau pathways in general, but a strong, consistent link to PSP specifically has not been proven. If there is an effect, it is likely small.Vascular burden and white-matter damage (nonspecific stress).
High blood pressure, diabetes, and microvascular disease do not cause PSP, but they may worsen gait and thinking by adding brain stress.Oxidative stress.
An imbalance between harmful oxygen molecules and cell defenses damages proteins, lipids, and DNA and may accelerate neuron loss.Sleep and glymphatic clearance disturbance (hypothesis).
Deep sleep helps the brain clear waste proteins. Poor sleep over time could reduce clearance, though this is a developing area.Unknown primary triggers (idiopathic nature).
Most people with PSP have no clear trigger. The disease reflects several small risks adding up over decades, leading to tau mis-handling in vulnerable brain regions.
Common symptoms
Symptoms vary, but PSP has a recognizable pattern. Each line below uses very simple words and explains why it happens.
Early balance problems and backward falls.
People lose the automatic reflexes that keep them upright, especially when turning or standing up. Falls often happen backward because the center of gravity shifts and the body is stiff.Trouble looking down and up (vertical gaze problems).
Fast eye movements, especially up-and-down, slow down and become limited. Reading, walking downstairs, and eating can be hard because the eyes cannot move where you want them to go.Stiff, upright posture with the head pulling back (retrocollis).
The neck and trunk muscles become rigid, making the body feel like a board. The head may tilt back without the person meaning to do it.Slowness of movement (bradykinesia) with poor response to levodopa.
Movements start slowly and feel effortful. Unlike Parkinson’s disease, the usual dopamine medicine often helps little or only briefly.Short, shuffling steps and “freezing” when starting or turning.
The feet may feel stuck to the floor, especially in tight spaces or when turning. This raises the chance of falls.Soft, slurred, or strained speech.
Speech muscles become stiff and poorly coordinated. Words can sound blurred, quiet, or choppy, and the rhythm can be broken.Swallowing difficulty and choking (dysphagia).
The timing of the swallow is off and the airway does not protect well. Food or liquid can go into the lungs and cause cough or pneumonia.Double vision, blurred vision, and light sensitivity.
Because eye movements are restricted and eyelids can spasm, people may see double, feel dazzled by bright light, or blink forcefully.Eyelid opening problems (blepharospasm and apraxia of eyelid opening).
The eyelids squeeze shut or do not open on command. People may hold the lids open with a finger to see.Thinking changes: slowed processing and poor executive function.
Tasks that need planning, switching between ideas, or holding a plan in mind become hard. People can seem “slowed” or easily distracted.Apathy and reduced motivation.
The drive to start activities fades. This is not laziness. It is a brain symptom, and it often improves with structured routines and cueing.Impulsivity or disinhibition.
Some people act too quickly or say things without filters. This comes from frontal-lobe network changes.Mood symptoms such as depression or anxiety.
Living with a progressive disease is stressful, and brain changes can also affect mood control. Both can be treated.Sleep problems.
Falling asleep, staying asleep, or acting out dreams can be issues. Sleep apnea can also appear or worsen.Urinary urgency and constipation.
Automatic body functions slow down and become uncoordinated. People may need to urinate often, or bowels may move less often and feel hard to pass.
Diagnostic tests
(Physical exam, manual bedside tests, lab & pathology, electrodiagnostic, and imaging.)
These tests help confirm the pattern, rule out other causes, and plan care. There is no single “PSP blood test.” Diagnosis rests on the story, the exam, and supportive tests.
A) Physical exam
Comprehensive eye-movement exam (focus on vertical saccades).
The clinician asks the person to look quickly up and down and side to side. In PSP the fast eye jumps (saccades) are slow and short, first for vertical movements. Later, even voluntary eye movements become very limited. This finding is central to PSP.Postural reflex testing and pull test.
With the person standing safely, the examiner gives a quick, small pull at the shoulders. People with PSP take too few or no steps to recover, especially backward, showing impaired automatic balance.Gait and posture observation.
The clinician watches how the person stands, starts to walk, turns, and stops. PSP often shows an upright, stiff posture, short steps, and difficulty turning without many small steps. The head may tilt back.Speech and bulbar exam.
The clinician listens for slurred, strained, or quiet speech and checks tongue and palate movement. Problems suggest risk for aspiration and guide referral to speech-language therapy.Bedside cognitive screening (e.g., clock draw, letter fluency).
Simple tests check attention, planning, mental flexibility, and verbal fluency. In PSP, executive skills are more affected than memory early on. This helps separate PSP from Alzheimer’s disease.
B) Manual bedside tests
Doll’s-head maneuver (vestibulo-ocular reflex check).
The examiner gently turns the head while asking the person to fixate on a target. In PSP, voluntary eye movement is limited, but this reflex can be relatively preserved early on, showing the problem lies “above” the eye-movement nuclei.Timed Up-and-Go (TUG).
The person stands up from a chair, walks three meters, turns, walks back, and sits. The time and the number of steps to turn show how freezing and postural instability affect mobility and safety.Anti-saccade task (bedside version).
The examiner moves a finger quickly; the person is asked to look the other way. Trouble suppressing the reflex and making the correct voluntary movement suggests frontal-executive dysfunction typical in PSP.3-ounce water swallow screen (initial safety screen).
The person drinks water without stopping. Coughing, changes in voice quality, or delayed swallowing suggest aspiration risk and need for full swallow study.“Applause sign” (motor perseveration).
The examiner claps three times and asks the person to do the same. People with PSP may keep clapping beyond three, showing difficulty stopping a movement once started, a sign of frontal control problems.
C) Lab and pathological tests
Blood tests to rule out mimics.
Thyroid function (TSH), vitamin B12 and folate, syphilis and HIV serology, copper and ceruloplasmin (if Wilson disease is a concern), basic chemistry, and blood count help exclude other causes of gait, eye, or cognitive problems. Normal results support a neurodegenerative diagnosis.Genetic testing (MAPT haplotype and others) when appropriate.
Routine genetic testing is not required for diagnosis, but in selected cases—early onset, strong family history, or research studies—testing can identify risk variants. A risk variant does not prove PSP and a normal test does not exclude it.Cerebrospinal fluid (CSF) biomarkers (research/adjunctive).
A lumbar puncture can measure proteins like total tau, phosphorylated tau, amyloid-β, and neurofilament light chain. Patterns can help distinguish PSP from Alzheimer’s disease and other disorders, though there is no single PSP-specific CSF marker in routine care yet.Neuropathology (gold standard, post-mortem).
Under the microscope, PSP shows 4-repeat tau deposits in neurons and glial cells, including “globose” tangles and “tufted astrocytes.” This is confirmatory but not a test used during life.
D) Electrodiagnostic and physiologic tests
Video-oculography or electro-oculography.
These tests precisely measure eye-movement speed and range. In PSP, vertical saccades are slowed and shortened. Objective numbers can support diagnosis and track change over time.EMG and swallowing physiology (e.g., fiberoptic endoscopic evaluation of swallowing).
Surface or needle EMG and endoscopic swallow exams show timing and strength of swallowing muscles. This helps set safe diet textures and plan therapy.Polysomnography (sleep study) when sleep symptoms are prominent.
A sleep study looks for sleep apnea or REM sleep behavior disorder, which can worsen daytime symptoms and increase fall risk. Treating sleep problems often improves daytime function.
E) Imaging tests
MRI brain with midbrain measures.
MRI often shows midbrain atrophy with relative pons preservation. This can look like a “hummingbird” or “penguin” shape on a side view. Quantitative measures such as the MR Parkinsonism Index (MRPI) increase diagnostic confidence.Dopamine transporter SPECT (DaTscan).
This imaging shows reduced dopamine terminals in the striatum, supporting a parkinsonian degeneration. It does not separate PSP from other atypical parkinsonian disorders by itself, but it helps rule out non-degenerative causes.FDG-PET (metabolic brain scan) when diagnosis is unclear.
This scan shows areas of lower sugar use in the brain. PSP often shows reduced metabolism in the frontal lobes and midbrain. It is not required for every patient but can be useful in complex cases.
Non-pharmacological treatments
Each item below says what it is, why it’s used (purpose), and how it helps (mechanism).
Specialist, team-based care — A neurologist (movement-disorders trained if possible) coordinates care with physiotherapy, occupational therapy, speech-language therapy, nutrition, eye care, social work, and palliative care. Purpose: align treatments with your goals and keep you safer at home. Mechanism: multidisciplinary problem-solving and regular review of falls, swallowing, mood, sleep, and medications. PubMedpspassociation.org.uk
Physiotherapy for balance and gait — Targeted balance, posture, and turning practice; large-amplitude, cue-based movement; safe rising from chairs and bed. Purpose: fewer falls and better confidence walking. Mechanism: motor learning and strength/balance retraining for axial rigidity and postural reflexes. pspassociation.org.ukPubMed
Strength and flexibility training — Progressive resistance for legs/hips, daily stretching for neck/shoulders/hamstrings/calves. Purpose: maintain mobility, reduce stiffness pains. Mechanism: preserves muscle power and joint range to compensate for bradykinesia and axial rigidity. pspassociation.org.uk
Cueing strategies (visual/auditory) — Metronomes, rhythmic music, floor lines, or laser walkers to start steps and improve stride. Purpose: reduce start hesitation and freezing-like episodes. Mechanism: external cues bypass impaired internal timing. pspassociation.org.uk
Treadmill or over-ground body-weight supported gait practice — Harnessed treadmill or supervised over-ground intervals. Purpose: safely practice longer stepping and endurance. Mechanism: repetitive task practice with fall protection enhances gait automaticity. PMC
Assistive devices chosen for PSP — Stable, reverse-brake walkers (e.g., U-shaped designs), high-friction shoes, hip protectors, transfer boards. Purpose: fewer backward falls and safer transfers. Mechanism: improves base of support and braking control for retropulsion. pspassociation.org.uk
Home safety modifications — Remove throw rugs/clutter, add grab bars and raised toilet seats, improve lighting, mark stair edges with high-contrast tape, use shower chairs. Purpose: cut fall risk where accidents happen most. Mechanism: environmental risk reduction tailored for early postural instability. pspassociation.org.uk
Occupational therapy (OT) — Task simplification, adaptive utensils, clothing aids, bed/seat positioning, calendar and reminder systems. Purpose: make daily activities doable and reduce caregiver strain. Mechanism: compensatory techniques for slowed processing, apathy, and hand/eye movement limits. pspassociation.org.uk
Speech therapy for voice and swallowing — Voice exercises (often louder, slower speech), breath support, and safe-swallow strategies (upright posture, chin-tuck, double-swallow, small sips/bites). Purpose: clearer communication and safer eating/drinking. Mechanism: strengthens and coordinates bulbar muscles; teaches compensations to limit aspiration. pspassociation.org.uk
Texture-modified diets & thickened liquids (with clinician guidance) — Right textures for current swallow ability. Purpose: lower choking and aspiration risk. Mechanism: slows flow and reduces airway penetration when pharyngeal timing is delayed. pspassociation.org.uk
Vision and eye-movement strategies — Teach head tilts and whole-body turns to compensate for vertical eye limitations; adjust reading stands higher; consider simple prisms as advised by specialists. Purpose: safer walking and easier reading/eating. Mechanism: substitutes neck/trunk movement when vertical saccades are slow. BioMed Central
Eyelid-opening behavioral tricks — Scheduled blinking, “brow lift” maneuvers, and dark lenses for light sensitivity; consider botulinum toxin if disabling (see medicines below). Purpose: improve functional vision. Mechanism: counters eyelid co-contraction/apraxia behaviorally. BioMed Central
Bowel program — Timed toileting, fluids, fiber foods, activity, with laxatives added by clinicians as needed. Purpose: prevent constipation, straining, and impaction. Mechanism: restores regular colonic rhythm with lifestyle first. pspassociation.org.uk
Sleep hygiene — Fixed wake/sleep times, daytime sunlight and activity, limiting late caffeine and screens; treat sleep apnea if present. Purpose: reduce daytime fatigue and falls from sleepiness. Mechanism: strengthens circadian cues and sleep quality. pspassociation.org.uk
Energy conservation & pacing — Break tasks into chunks, sit for grooming/cooking, plan high-energy activities when most alert. Purpose: maintain independence longer. Mechanism: matches effort to fluctuating stamina. pspassociation.org.uk
Cognitive/behavioral supports — Whiteboards, alarms, pill organizers; simple routines; caregiver coaching for apathy and impulsivity. Purpose: keep daily structure and safety. Mechanism: external executive supports while frontal circuits are affected. Memory and Aging Center
Psychological support & caregiver groups — Counseling for mood and coping; peer support (e.g., CurePSP resources). Purpose: reduce isolation and distress; plan for future needs. Mechanism: education, skills training, and social connection. psp.org
Driving and community mobility planning — Early discussion and formal assessments; arrange alternatives (transport services). Purpose: prevent crashes and preserve autonomy. Mechanism: recognizes slowed saccades, reduced scanning, and poor balance. pspassociation.org.uk
Early palliative-care involvement — Symptom control, goal-setting, caregiver support, and timely equipment planning. Purpose: match care to values and avoid crises. Mechanism: proactive, whole-person management from early stages. BMJ Pain News
Advance care planning — Document feeding preferences, resuscitation wishes, and decision-makers before emergencies. Purpose: reduce uncertainty later. Mechanism: legal and communication tools aligned with disease course. BMJ Pain News
Medicine options
(Dose ranges are typical starting points; your doctor will individualize and watch for side effects.)
Carbidopa/levodopa (dopamine replacement) — 25/100 mg tablets, often ½–1 tablet 2–3×/day and adjusted. Purpose: sometimes eases slowness or stiffness, especially in PSP-parkinsonism. Mechanism: boosts dopamine signaling. Notes: Only a minority benefit; try an adequate, time-limited trial; monitor for nausea, light-headedness, hallucinations. PMC
Amantadine (NMDA-modulating antiparkinsonian) — 100 mg once or twice daily, titrating if helpful. Purpose: may improve gait energy, axial rigidity, or speech clarity in some. Mechanism: dopaminergic and antiglutamatergic effects. Notes: Evidence is mixed; side effects include confusion, ankle swelling, livedo. BMJ Pain NewsMDS Abstracts
Botulinum toxin injections (onabotulinum/abobotulinum/incobotulinumA; rimabotulinumB) — Injections to eyelid muscles for apraxia of eyelid opening or to salivary glands for drooling. Purpose: improve functional vision or reduce sialorrhea. Mechanism: locally blocks acetylcholine release in overactive muscles/glands. Notes: Effects are local and temporary (≈3 months). PubMed+1Frontiers
Dextromethorphan/quinidine 20/10 mg (for pseudobulbar affect) — 1 capsule twice daily. Purpose: decreases sudden, inappropriate laughing/crying spells. Mechanism: sigma-1 and glutamatergic modulation; quinidine boosts dextromethorphan levels. Notes: watch QT interval and drug interactions. PubMedE-JMD
SSRIs (e.g., sertraline, citalopram) or SNRIs — Standard antidepressant doses. Purpose: treat depression, anxiety, and emotional lability common in PSP. Mechanism: serotonergic/noradrenergic stabilization. Notes: can help mood and coping; watch hyponatremia and GI upset. BMJ Pain News
Glycopyrrolate tablets or transdermal scopolamine patch; sublingual atropine drops — Glycopyrrolate 1 mg up to 3×/day; scopolamine patch q72h; 1% atropine drops under the tongue as directed. Purpose: reduce drooling if behavioral and posture changes aren’t enough. Mechanism: anticholinergic reduction of salivary flow. Notes: monitor for dry mouth, constipation, confusion; older adults are sensitive. Botulinum to glands is often better tolerated. Lippincott Journals
Baclofen or tizanidine (antispasticity) — Baclofen 5–10 mg three times daily; tizanidine 2–4 mg at night then titrate. Purpose: ease stiffness or spasms that hinder transfers and sleep. Mechanism: GABA-B agonism (baclofen) or α2-agonism (tizanidine). Notes: can cause sleepiness and falls; go slow. BMJ Pain News
Clonazepam (for myoclonus/REM-sleep behavior disorder or severe eyelid dystonia adjunct) — 0.25–0.5 mg at bedtime. Purpose: calmer sleep or reduced jerks. Mechanism: GABA-A enhancement. Notes: sedation and falls are the main risks. BMJ Pain News
Modafinil (wake-promoting) — 100–200 mg in the morning. Purpose: daytime alertness when sleepiness limits therapy time. Mechanism: promotes wakefulness via catecholamine/histamine systems. Notes: can raise blood pressure and cause headaches. BMJ Pain News
Melatonin (sleep initiation) — 1–3 mg 1–2 hours before bed. Purpose: improve sleep onset and REM behavior disorder adjunct. Mechanism: circadian signaling. Notes: generally well tolerated; still coordinate with your clinician. BMJ Pain News
Dietary “molecular” supplements
Vitamin D3 (800–2,000 IU/day; adjust to blood level) — Function: bone strength and falls/fracture prevention support. Mechanism: calcium homeostasis and muscle function.
Calcium (diet first; otherwise 500–600 mg with meals once/twice daily) — Function: bone health; pair with vitamin D. Mechanism: mineral for bone matrix.
Omega-3 EPA/DHA (≈1–2 g/day) — Function: heart and brain supportive; anti-inflammatory. Mechanism: membrane effects and eicosanoid balance.
Coenzyme Q10 (100–300 mg/day with fat) — Function: mitochondrial support; Note: PSP trials have not shown clear benefit. Mechanism: electron transport antioxidant. PMC
Creatine monohydrate (3–5 g/day) — Function: muscle power/endurance during therapy. Mechanism: phosphocreatine energy buffering.
Magnesium glycinate (200–400 mg/day) — Function: muscle relaxation, sleep support, constipation aid. Mechanism: smooth muscle/neuronal modulation.
B-complex with B12 & folate (dose per label) — Function: corrects deficiencies that worsen fatigue or neuropathy. Mechanism: methylation and nerve support.
Psyllium husk/fiber (5–10 g/day with water) — Function: constipation reduction. Mechanism: stool bulk and motility.
Probiotics (daily) — Function: bowel regularity and antibiotic-associated diarrhea prevention. Mechanism: gut microbiome support.
Curcumin with piperine (e.g., 500–1,000 mg/day) — Function: general anti-inflammatory support; Note: no disease-modifying PSP data. Mechanism: NF-κB and cytokine modulation.
Regenerative/stem cell” drug approaches
Gosuranemab (BIIB092; anti-tau mAb) — IV antibody targeting extracellular N-terminal tau. Status: robust target engagement but no clinical benefit on the PSP Rating Scale at 52 weeks in a phase 2 trial. Implication: lowered CSF tau didn’t translate into slower decline. PubMed
Tilavonemab (ABBV-8E12; anti-tau mAb) — Status: a large randomized trial showed no improvement vs placebo; extension studies were stopped early; safety acceptable. The LancetPharmaceutical Research & Development
Semorinemab (anti-tau mAb) — Status: failed in Alzheimer’s disease trials; not demonstrated effective in PSP. ir.acimmune.comPMC
Bepranemab (UCB0107; anti-tau mAb) — Status: early PSP safety studies; development for PSP paused/shifted toward Alzheimer’s focus; not an approved therapy. UCBpsp.org
TPI-287 (microtubule stabilizer) — Status: basket trials across tauopathies noted tolerability issues and no clear efficacy signal in PSP; not a treatment. PMC
Mesenchymal stem cells (MSC), intra-arterial — Status: small phase-I/II explorations focused on safety; no proven functional benefit; still experimental. PMCBioMed Central
Procedures/surgeries
Feeding tube (PEG) placement — Why: severe swallowing problems, weight loss, or recurrent aspiration. How it helps: reliable nutrition/fluids/med delivery and may reduce choking risk; does not halt PSP.
Tracheostomy (select cases) — Why: chronic airway protection problems or repeated aspiration pneumonia despite max therapy. How it helps: secures airway and allows secretion management; high care needs.
Frontalis suspension or upper-eyelid myectomy (for refractory apraxia of eyelid opening) — Why: botulinum toxin no longer adequate and “functional blindness” limits life. How it helps: links eyelid to forehead muscle or removes overactive muscle strips to restore opening. PMCNCBI
Salivary-gland procedures (e.g., duct ligation/relocation or gland excision) — Why: drooling persists despite medication and botulinum. How it helps: reduces saliva flow; risks include dry mouth and dental issues. AGs Journals
Deep brain stimulation (DBS) of the pedunculopontine nucleus—experimental — Why: attempted for severe gait freezing/falls. How it helps: may change gait parameters at certain frequencies, but no consistent, meaningful clinical benefit in PSP; not standard care. PubMedFrontiers
Prevention tips
Fall-proof the home (grab bars, lighting, remove trip hazards).
Use the right walker and learn safe transfers with a therapist.
Hip protectors if falls persist.
Swallow safety: upright posture, small bites/sips, matched textures; stop eating at first cough.
Vaccinations: influenza, pneumococcal, COVID-19 (and RSV where appropriate) to lower pneumonia risk.
Daily oral care to cut aspiration-pneumonia bacteria load.
Bone health plan (vitamin D, calcium, DEXA when indicated).
Vision aids & lighting to compensate for vertical gaze limits.
Medication review to trim sedatives and anticholinergics that worsen confusion and falls.
Advance care planning to align urgent decisions with your wishes. NINDSpspassociation.org.uk
When to see a doctor urgently
Choking, repeated coughing with meals, or weight loss.
Falls, head injury, or new inability to stand/walk safely.
Fever, chest pain, shortness of breath, or signs of pneumonia.
New confusion, severe sleepiness, or sudden behavior change.
Rapid vision changes or inability to open the eyes that blocks daily life.
Side effects from medicines (fainting, hallucinations, severe constipation, allergic reactions). NINDS
What to eat & what to avoid
Choose moist, soft proteins (eggs, yogurt, flaky fish) over dry meats or crusty breads that crumble.
Choose well-cooked vegetables and stews over raw salads with stringy leaves.
Choose fruit purees/ripe bananas over mixed-nuts or seed mixes.
Choose oatmeal, porridge, or soaked cereals over dry granola.
Choose mashed potatoes/squash over dry rice.
Choose smoothies with added protein over thin liquids when your SLP advises thickening.
Choose small, frequent meals over large plates that tire you out.
Choose water sips between bites over washing food down with large gulps.
Choose decaf/herbal in evenings over late caffeine that disrupts sleep.
Choose minimal alcohol over drinks that worsen balance and swallowing.
(A speech-language pathologist should tailor textures and thickener levels for you.) pspassociation.org.uk
FAQs
1) Is PSP the same as Parkinson’s disease?
No. PSP overlaps with Parkinson’s but typically has earlier backward falls and vertical eye-movement slowing; tremor is less prominent; medicines help less. NINDS
2) What truly causes PSP?
We don’t know the trigger. The hallmark is abnormal tau protein accumulation damaging specific brain circuits. NINDS
3) How is PSP diagnosed?
Doctors use clinical criteria focused on eye movements, early falls, slowness, and cognitive/behavioral signs. MRI and other tests mainly exclude look-alikes. PMC
4) Are there subtypes?
Yes—patterns such as PSP-Richardson’s, PSP-parkinsonism, PSP-gait freezing, PSP-frontal, etc. They share the same underlying tau process but start differently. PMC
5) Does levodopa work?
Some people (a minority) report partial, temporary benefit, especially in PSP-parkinsonism, but many do not. A time-limited, adequately dosed trial is reasonable. PMC
6) Is amantadine worth trying?
It can help energy, gait, or speech clarity in some, but evidence is mixed and side effects can occur; it’s a personalized decision. BMJ Pain News
7) What about anti-tau antibodies?
Multiple antibodies hit the target but failed to slow PSP in trials so far, so they are not treatments today. PubMedThe Lancet
8) Can stem cells cure PSP?
No current proof. Early studies have focused on safety; benefit hasn’t been shown. PMC
9) Are there eye treatments for difficulty opening eyelids?
Yes. Botulinum injections can help in many; surgery (frontalis suspension/myectomy) is a backup for severe cases. PubMedPMC
10) What helps drooling?
Posture and swallow strategies first; then anticholinergic options or salivary-gland botulinum injections, which have good evidence. PubMedFrontiers
11) Is DBS an option?
DBS of the pedunculopontine nucleus has inconsistent results and hasn’t shown meaningful overall benefit in PSP; it’s not standard. PubMed
12) What’s the usual course?
Progression varies. Focus on safety and quality of life with proactive team care and early planning. NINDS
13) Can exercise really help?
Yes—supervised, tailored programs improve function and confidence even though they don’t change the underlying disease. PMC
14) Who can guide swallowing and diet?
A speech-language pathologist and dietitian assess swallowing and plan safe textures and hydration. pspassociation.org.uk
15) Where can families learn more?
CurePSP and national neurology resources offer education, groups, and planning tools. psp.org
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: August 23, 2025.
